Literature DB >> 12846127

The multidisciplinary approach to bone metastases.

Ronald H Blum1, Danielle Novetsky, Danielle Shasha, Stewart Fleishman.   

Abstract

With recent advances in the management of cancer, the clinical course of patients with metastatic bone disease is more likely to be prolonged and accompanied by morbidity, including severe pain, hypercalcemia, pathologic fracture, and spinal cord and/or nerve root compression. The early identification of patients at higher risk for developing bone metastases enables practitioners to be proactive in their diagnosis and treatment. A multidisciplinary approach that integrates the diagnosis and treatment of the cancer, symptom management, and rehabilitation ensures optimal care. Bisphosphonates can reduce the number of skeletal-related complications, delay the onset of progressive disease in bone, and relieve metastatic bone pain caused by a variety of solid tumors with a resulting enhanced quality of life. The complexity of the clinical problem and the need to involve an array of health-care providers present a logistical and clinical challenge. A strong argument is made for a thematically integrated bone metastases program as part of the primary care of patients with cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12846127

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  13 in total

1.  Palliative embolisation for advanced bone sarcomas.

Authors:  A F Mavrogenis; G Rossi; G Altimari; T Calabrò; A Angelini; E Palmerini; E Rimondi; P Ruggieri
Journal:  Radiol Med       Date:  2012-08-09       Impact factor: 3.469

2.  Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer.

Authors:  Tamara King; Anna Vardanyan; Lisa Majuta; Ohannes Melemedjian; Ray Nagle; Anne E Cress; Todd W Vanderah; Josephine Lai; Frank Porreca
Journal:  Pain       Date:  2007-08-15       Impact factor: 6.961

3.  Impact of a Specialized Outpatient Clinic on Bone Metastasis and Its Burden on Spine Surgeons.

Authors:  Hiroyuki Tsuchie; Naohisa Miyakoshi; Michio Hongo; Hiroyuki Nagasawa; Yuji Kasukawa; Daisuke Kudo; Ryota Kimura
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

4.  A multidisciplinary bone metastases clinic at Toronto Sunnybrook Regional Cancer Centre - A review of the experience from 1999 to 2005.

Authors:  Kathy K Li; Emily Sinclair; Joan Pope; Macey Farhadian; Kristin Harris; Julie Napolskikh; Albert Yee; Lawrence Librach; Lesia Wynnychuk; Cyril Danjoux; Edward Chow; On Behalf Of The Bone; Metastases Team
Journal:  J Pain Res       Date:  2008-09-01       Impact factor: 3.133

5.  CORR Insights®: What Is the Value of Undergoing Surgery for Spinal Metastases at Dedicated Cancer Centers?

Authors:  Stein J Janssen
Journal:  Clin Orthop Relat Res       Date:  2021-06-01       Impact factor: 4.755

6.  Disease modifying actions of interleukin-6 blockade in a rat model of bone cancer pain.

Authors:  Bethany Remeniuk; Tamara King; Devki Sukhtankar; Amy Nippert; Nancy Li; Fuying Li; Kejun Cheng; Kenner C Rice; Frank Porreca
Journal:  Pain       Date:  2018-04       Impact factor: 7.926

Review 7.  Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology.

Authors:  H Shibata; S Kato; I Sekine; K Abe; N Araki; H Iguchi; T Izumi; Y Inaba; I Osaka; S Kato; A Kawai; S Kinuya; M Kodaira; E Kobayashi; T Kobayashi; J Sato; N Shinohara; S Takahashi; Y Takamatsu; K Takayama; K Takayama; U Tateishi; H Nagakura; M Hosaka; H Morioka; T Moriya; T Yuasa; T Yurikusa; K Yomiya; M Yoshida
Journal:  ESMO Open       Date:  2016-03-16

8.  An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries.

Authors:  Jean-Jacques Body; Francesca Gatta; Erwin De Cock; Sunning Tao; Persefoni Kritikou; Pauline Wimberger; Jeroen Mebis; Marc Peeters; Paolo Pedrazzoli; Augusto Caraceni; Vincenzo Adamo; Guy Hechmati
Journal:  Support Care Cancer       Date:  2017-04-21       Impact factor: 3.603

Review 9.  Considering renal risk while managing cancer.

Authors:  Vahakn B Shahinian; Amit Bahl; Daniela Niepel; Vito Lorusso
Journal:  Cancer Manag Res       Date:  2017-05-16       Impact factor: 3.989

10.  Improvement of morphine-mediated analgesia by inhibition of β-arrestin2 expression in mice periaqueductal gray matter.

Authors:  Yuting Li; Xing Liu; Chang Liu; Jiuhong Kang; Jingyu Yang; Gang Pei; Chunfu Wu
Journal:  Int J Mol Sci       Date:  2009-03-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.